Compare GSK Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PANACEA BIOTECH - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PANACEA BIOTECH GSK PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 33.0 10.5 313.5% View Chart
P/BV x 13.1 2.2 589.8% View Chart
Dividend Yield % 1.2 0.0 -  

Financials

 GSK PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
PANACEA BIOTECH
Mar-19
GSK PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs3,595354 1,016.7%   
Low Rs1,253138 906.7%   
Sales per share (Unadj.) Rs184.774.6 247.7%  
Earnings per share (Unadj.) Rs26.36.7 393.7%  
Cash flow per share (Unadj.) Rs29.215.5 188.2%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs126.357.2 220.8%  
Shares outstanding (eoy) m169.4061.25 276.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.13.3 398.0%   
Avg P/E ratio x92.236.8 250.4%  
P/CF ratio (eoy) x83.115.9 523.8%  
Price / Book Value ratio x19.24.3 446.4%  
Dividend payout %76.10-   
Avg Mkt Cap Rs m410,62615,061 2,726.3%   
No. of employees `0005.02.3 214.3%   
Total wages/salary Rs m5,3721,471 365.2%   
Avg. sales/employee Rs Th6,306.71,973.6 319.5%   
Avg. wages/employee Rs Th1,083.1635.6 170.4%   
Avg. net profit/employee Rs Th898.0176.8 507.9%   
INCOME DATA
Net Sales Rs m31,2814,567 684.9%  
Other income Rs m1,02345 2,283.9%   
Total revenues Rs m32,3044,612 700.5%   
Gross profit Rs m6,0092,030 296.0%  
Depreciation Rs m486540 90.0%   
Interest Rs m61,048 0.6%   
Profit before tax Rs m6,540486 1,345.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,37377 3,077.8%   
Profit after tax Rs m4,454409 1,088.7%  
Gross profit margin %19.244.4 43.2%  
Effective tax rate %36.315.9 228.8%   
Net profit margin %14.29.0 159.0%  
BALANCE SHEET DATA
Current assets Rs m20,0612,415 830.9%   
Current liabilities Rs m14,5439,077 160.2%   
Net working cap to sales %17.6-145.9 -12.1%  
Current ratio x1.40.3 518.6%  
Inventory Days Days5765 87.2%  
Debtors Days Days1471 19.8%  
Net fixed assets Rs m14,3438,333 172.1%   
Share capital Rs m1,69461 2,763.5%   
"Free" reserves Rs m19,7043,443 572.3%   
Net worth Rs m21,3983,504 610.7%   
Long term debt Rs m2461 0.4%   
Total assets Rs m39,11313,755 284.4%  
Interest coverage x1,091.01.5 74,532.1%   
Debt to equity ratio x00.1 0.1%  
Sales to assets ratio x0.80.3 240.9%   
Return on assets %11.410.6 107.6%  
Return on equity %20.811.7 178.3%  
Return on capital %31.938.7 82.5%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m5341,203 44.4%   
Fx outflow Rs m7,091467 1,519.5%   
Net fx Rs m-6,557736 -890.4%   
CASH FLOW
From Operations Rs m3,9941,049 380.8%  
From Investments Rs m-1,433-54 2,679.3%  
From Financial Activity Rs m-3,584-1,011 354.3%  
Net Cashflow Rs m-1,023-20 5,193.9%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.6 1,700.0%  
FIIs % 23.8 1.3 1,830.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 23.6 65.3%  
Shareholders   102,036 10,259 994.6%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   SANOFI INDIA  ASTRAZENECA PHARMA  BIOCON   STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 181 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours but ended their session off day's high.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 20, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - AUROBINDO PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS